Silence Therapeutics to Participate in September Investor Conferences

Audio By Carbonatix

LONDON--(BUSINESS WIRE)--Sep 2, 2025--

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences:

• Morgan Stanley Global Healthcare Conference
  Fireside Chat on Tuesday, September 9, 2025 at 5:35 p.m. ET

• H.C. Wainwright Global Investment Conference
  Fireside Chat on Wednesday, September 10, 2025 at 12:00 p.m. ET

The webcasts can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com.

About Silence Therapeutics
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. For more information, please visit https://www.silence-therapeutics.com/.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250902137472/en/

CONTACT: Inquiries:

Silence Therapeutics plc

Gem Hopkins, VP, Head of IR and Corporate Communications

[email protected]

Tel: +1 (646) 637-3208

KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH

SOURCE: Silence Therapeutics plc

Copyright Business Wire 2025.

PUB: 09/02/2025 08:00 AM/DISC: 09/02/2025 08:00 AM

http://www.businesswire.com/news/home/20250902137472/en